







Spotlight on MPTs Addressing STIs

	Preclinical	Phase I	Phase II	Phase III
HIV & other STIs				
HIV, Gonorrhea				
HIV, HSV				
HIV, BV				
HIV, other STIs & Contraceptives				
HIV, HSV, Pregnancy				
HIV, HSV, Chlamydia, Gonorrhea, Pregnancy				
HIV, HSV, BV, Chlamydia, Gonorrhea, Pregnancy				
HIV & other STIs		HIV, other STIs & Contraception		
3		4		

¹ The dual prevention pill is undergoing bioequivalence studies because the drug components are already approved separately, but not in combination.

² This product addresses HIV and Bacterial Vaginosis (BV). BV is not sexually transmitted but can be linked to sexual activity.

Adapted from: *The Initiative for MPTs (IMPT) Product Development Database; Treatment Action Group (TAG) 2024 Pipeline Review; MATRIX R&D Landscape Review 2024.*